Digital Breast Tomosynthesis Screening In women presenting with signs or symptoms, including a palpable breast mass, screening DBT, with or without DM, is unnecessary for confirmation of benignity. Screening mammography is provided to women without signs or symptoms of breast disease. FDG-PET Breast Dedicated If a benign entity has been found on US and is the definitive correlate for a palpable mass, there is no role for FDG- PET breast dedicated in women <30 years of age [2]. Image-Guided Core Biopsy Breast If a benign entity has been found on US and is the definitive correlate for a palpable mass, there is no role for tissue sampling. The likelihood of a palpable mass in a young woman that is benign on both clinical examination and US resulting in a cancer is extremely low; one study prospectively evaluating US-guided core biopsy in 248 young women <25 years of age with clinically benign masses and predominantly benign findings found no cancers in this group [52]. Image-Guided Fine Needle Aspiration Breast If a benign entity has been found on US and is the definitive correlate for a palpable mass, there is no role for image- guided FNAB in women <30 years of age. Mammography Diagnostic If a benign entity has been found on US and is the definitive correlate for a palpable mass, there is no role for further evaluation with diagnostic mammography in women <30 years of age. Mammography Screening In women presenting with signs or symptoms, including a palpable breast mass, screening mammography is unnecessary for confirmation of benignity. Screening mammography is provided to women without signs or symptoms of breast disease. MRI Breast If a benign entity has been found on US and is the definitive correlate for a palpable mass, there is no role for MRI of the breast with or without IV contrast in women <30 years of age [2,23-25].
Palpable Breast Masses. Digital Breast Tomosynthesis Screening In women presenting with signs or symptoms, including a palpable breast mass, screening DBT, with or without DM, is unnecessary for confirmation of benignity. Screening mammography is provided to women without signs or symptoms of breast disease. FDG-PET Breast Dedicated If a benign entity has been found on US and is the definitive correlate for a palpable mass, there is no role for FDG- PET breast dedicated in women <30 years of age [2]. Image-Guided Core Biopsy Breast If a benign entity has been found on US and is the definitive correlate for a palpable mass, there is no role for tissue sampling. The likelihood of a palpable mass in a young woman that is benign on both clinical examination and US resulting in a cancer is extremely low; one study prospectively evaluating US-guided core biopsy in 248 young women <25 years of age with clinically benign masses and predominantly benign findings found no cancers in this group [52]. Image-Guided Fine Needle Aspiration Breast If a benign entity has been found on US and is the definitive correlate for a palpable mass, there is no role for image- guided FNAB in women <30 years of age. Mammography Diagnostic If a benign entity has been found on US and is the definitive correlate for a palpable mass, there is no role for further evaluation with diagnostic mammography in women <30 years of age. Mammography Screening In women presenting with signs or symptoms, including a palpable breast mass, screening mammography is unnecessary for confirmation of benignity. Screening mammography is provided to women without signs or symptoms of breast disease. MRI Breast If a benign entity has been found on US and is the definitive correlate for a palpable mass, there is no role for MRI of the breast with or without IV contrast in women <30 years of age [2,23-25].